News Center

News Center

News Center

First Patient Dosed in Global Pivotal Phase 3 Clinical Trial for BioNTech and DualityBio’s B7-H3 ADC DB-1311/BNT324 in Metastatic Castration-Resistant Prostate Cancer

2025-04-29

DualityBio Presented Early Clinical and Preclinical Data for Novel ADC Therapy Candidates at AACR 2025
2025-04-24

ASCO 2025: DualityBio to present data from ADC pipeline in oral presentations at 2025 ASCO Annual Meeting
2025-04-15

DualityBio (9606.HK) Officially Lists on Hong Kong Stock Exchange, Embarking on a New Chapter
2025-04-07

Duality Bio Appoints Hua Mu as Global Chief Medical Officer
2025-01-13

Voluntary Annuoncement Cooperation Between 3SBio Inc. And Duality Biol Ogics In Respect Of Her2 Adc Drug
2025-01-08

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

«
1
2
3
4
5
6
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai